Screener
Haemonetics HAE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
FAQ
- What is Haemonetics's cash & equivalents?
- Haemonetics (HAE) reported cash & equivalents of $223.38M in Q2 2026.
- How has Haemonetics's cash & equivalents changed year-over-year?
- Haemonetics's cash & equivalents decreased by 23.7% year-over-year, from $292.9M to $223.38M.
- What is the long-term trend for Haemonetics's cash & equivalents?
- Over 5 years (2021 to 2026), Haemonetics's cash & equivalents has grown at a 5.0% compound annual growth rate (CAGR), from $192.31M to $245.44M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Haemonetics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude